<DOC>
	<DOCNO>NCT00171899</DOCNO>
	<brief_summary>The study assess role high-dose imatinib mesylate , patient take imatinib mesylate least 1 year standard dose , achieve major molecular response ( measure level chronic myelogenous leukemia ) versus standard dose .</brief_summary>
	<brief_title>Study Comparing Standard Dose High-dose Imatinib Mesylate Patients With Chronic Phase Philadelphia Chromosome Positive ( Ph+ ) Chronic Myelogenous Leukemia ( CML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Chronic myelogenous leukemia Philadelphia chromosome 18 year old Patients must take imatinib mesylate standard dose least 12 month achieve complete cytogenetic response major molecular response . Patients cardiac problem congestive heart failure , myocardial infarction within last 6 month Patients uncontrolled medical disease uncontrolled diabetes , chronic renal ( kidney ) disease active uncontrolled infection . Patients current primary malignancy malignancy require active intervention Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Complete cytogenetic response</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Major molecular response</keyword>
	<keyword>Chronic phase Ph+ Chronic Myelogenous Leukemia</keyword>
</DOC>